A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 6, 2013, Pages 613-621

  Naismith, G D ^a   Smith, L A ^a   Barry, S J E ^b   Munro, J I ^a   Laird, S ^a   Rankin, K ^a   Morris, A J ^a   Winter, J W ^a   Gaya, D R ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

ADULT; ANALYTICAL PARAMETERS; CASE RELIABILITY; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONSISTENCY; CONTROLLED STUDY; CROHN DISEASE; CUT OFF LEVEL; FECAL CALPROTECTIN LEVEL; FECAL CALPROTECTIN TEST; FECES ANALYSIS; FECES LEVEL; FEMALE; HUMAN; ILEUM; INTRA INDIVIDUAL VARIABILITY; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; REMISSION; REPRODUCIBILITY; REVIEW;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; CROHN DISEASE; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 84874105203     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12221     Document Type: Review

References (34)

1. Tibble JA, Teahon K, Thjodleifsson B, et al,. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 506-13.
2. Summerton CB, Longlands MG, Wiener K, Shreeve DR,. Faecal calprotectin: marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 841-5.
3. Schoepfer AM, Beglinger C, Straumann A, et al,. Fecal Calprotectin correlates more closely with with simple endoscopic score for Crohn's disease (SES-CD) than CRP, Leukocytes and the CDAI. Inflamm Bowel Dis 2010; 105: 162-9.
4. Roseth AG, Schmidt PN, Fagerhol MK,. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-4.
5. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H,. Assessment of the neutrophil dominating protein calprotectin in feces A methodologic study. Scand J Gastroenterol 1992; 27: 793-8.
6. Roseth AG, Aadland E, Grzyb K,. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1017-20.
7. Kallel L, Ayadi I, Matri S, et al,. Fecal calprotectin is a predictive marker of replase in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010; 22: 340-5.
8. Laharie D, Mesli S, El Hajbi F, et al,. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011; 34: 462-9.
9. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I,. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
10. Costa F, Mumolo MG, Ceccarelli L, et al,. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-8.
11. D'Inca R, Dal Pont E, Di Leo V, et al,. Can Calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008; 103: 2007-14.
12. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al,. Does Fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 2010; 4: 144-52.
13. Gisbert JP, Bermejo F, Perez-Calle JL, et al,. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190-8.
14. Sipponen T, Savilahti E, Karkkainen P, et al,. Fecal Calprotectin, lactoferrin and endoscopic disease activity in monitoring anti-TNF alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14: 1392-8.
15. Moum B, Jahnsen J, Bernklev T,. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis 2010; 16: 1091-2.
16. Von Roon AC, Karamountzos L, Purkayastha S, et al,. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102: 803-13.
17. Best WR, Becktel JM, Singleton JW, Kern F Jr, et al,. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
18. Shoukri M, Asyali M, Donner A,. Sample size requirements for the design of reliability study: review and new results. Stat Methods Med Res 2004; 13: 251-71.
19. Shrout PE, Fleiss JL,. Intraclass correlation: uses in assessing rater reliability. Psychol Bull 1979; 86: 420-8.
20. Fleiss JL,. Measuring nominal scale agreement among many raters. Psychol Bull 1971; 76: 378-82.
21. Donner A, Eliasziw M,. A goodness-of-fit approach to inference procedures for the kappa statistic: confidence interval construction, significance-testing and sample size estimation. Stat Med 1992; 11: 1511-9.
22. Sutherland AD, Geary RB, Frizelle FA,. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008; 51: 1283-91.
23. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F,. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leucocytes, CRP and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32-9.
24. Gisbert JP, McNicholl AG,. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009; 41: 55-66.
25. Logan R, Hargreaves P, Stoyloff R,. Centre for Evidence-based purchasing. Value of Calprotectin in screening out Irritable Bowel Syndrome: evidence Review. London: NHS Purchasing and Supply Agency, 2009; CEP09026.
26. Manz M, Burri E, Rothen C, et al,. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012; 12: 5.
27. Van Rheenen PF, Van de Vijver E, Fidler V,. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
28. Wagner M, Peterson GB, Ridefelt P, Sangfelt P, Carlson M,. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14: 5584-9.
29. Palmon R, Brown S, Ullman TA, et al,. Calprotectin and lactoferrin decrease with maintenance infliximab administration [abstract]. Gastroenterology 2006; 130 (Suppl. 2): A-212.
30. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ,. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin and PMN-elastase, CRP and clinical indices. Am J Gastroenterol 2008; 103: 162-9.
31. Jones J, Loftus EV, Panaccione R, et al,. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008; 6: 1218-24.
32. Loser C, Mollgaard A, Folsch UR,. Faecal elastase: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut 1996; 39: 580-6.
33. Husebye E, Ton H, Johne B,. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001; 96: 2683-7.
34. Gilbert JA, Ahlquist DA, Mahoney DW,. Fecal marker variability in colorectal cancer: Calprotectin versus haemoglobin. Scand J Gastroenterol 1996; 31: 1001-5.